Introduction:
National Resilience plans to invest US$225 million to increase PFS and Cartridge fill/finish capabilities in Cincinnati, USA.
Features:
The facility aims to enhance its existing fill/finish capabilities by increasing its capacity for pre-filled syringes (PFS) and cartridge fill/finish.
The facility possesses expertise in handling drug substance and drug product for Gene Therapy medications. Additionally, it has 45,000 square feet of unused space, which can be utilised for further expansion, particularly in drug product operations.
The capacity provides over 200 million units to partners across its manufacturing network by 2025, supporting various modalities and therapeutic indications, including GLP-1.
As part of its expansion strategy, the facility will install a new cutting-edge Bausch & Strobel Isolator filler to accommodate Vials and PFS, ensuring flexibility and maintaining quality standards through its barrier isolation technology.
This expansion meets the increasing demand within the biomanufacturing industry's drug product sector, effectively meeting the evolving needs of the industry.
Moreover, the facility is expanding its drug product capabilities at the RTP facility in North Carolina by employing a modular design within its segregated expansion space. This approach aims to facilitate drug product manufacturing across multiple modalities.
The new drug product site is expected to be opened by 2025.
Specifications:
Name National Resilience
Type New Construction
Budget US$225 million
Year 2025
